- Nib maintains its full-year underlying operating profit forecast, expecting between A$235 million to A$250 million.
- The company anticipates operating losses for its division, nib NZ, in the second half of 2025.
- Rob Hennin, the CEO of nib NZ and nib Travel, will step down from his position.
- A recruitment process is currently underway to find a new CEO, with Hennin continuing in his role during the transition period.
- In terms of analyst recommendations, there are five buy ratings, six hold ratings, and one sell rating for the company.
- All comparisons to past results are based on the company’s original reported disclosures.
A look at nib holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts utilizing the Smartkarma Smart Scores indicate that nib Holdings has a promising long-term outlook. The company’s scores for Value, Dividend, Growth, Resilience, and Momentum are all above average, reflecting a favorable overall assessment. With a solid foundation in place across these key factors, nib Holdings is positioned well to navigate the competitive health insurance market.
As a company that offers a range of health insurance products, including coverage for ambulance costs, dental, optical, and physiotherapy expenses, nib Holdings caters to various healthcare needs. Its strong scores in Dividend, Growth, Resilience, and Momentum signify a robust operational performance and growth potential in the foreseeable future. Investors may view nib Holdings as a promising investment option based on these positive indicators from Smartkarma’s assessment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
